Prospective and Randomized Comparison of Combined Androgen Blockade Versus Combination with Oral UFT as an Initial Treatment for Prostate Cancer

Kuriyama, Manabu; Takahashi, Yūzō; Sahashi, M.; Ono, Yoshinari; Tanaka, Takuji; Shimizu, Hiroyuki; Ohshima, Shinichi

doi:10.1093/jjco/hye008

Cited by 15 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 -30,40,43 Others were limited in many respects, including presentation of results and missing data reporting. 25,34,38,48,49 Prostate carcinoma patients are usually older than the general cancer population. Thus, the treatment is often debilitating without significantly prolonging survival.…”

Section: Discussionmentioning

confidence: 99%

“…32 Nevertheless, some trials reported limited information about the nature of the HRQOL measure used while others created ad hoc measures without giving any information about the developmental process. 25,38,48,49 …”

Section: Hrqol Assessment Methodologymentioning

confidence: 99%

“…[47][48][49] Bicalutamide, the therapy against which most treatment comparisons were made, was used in seven trials. 26,27,35,36,39,44,46 Radiotherapy was limited to four RCTs.…”

Section: Demographics and Trial Designsmentioning

confidence: 99%

See 2 more Smart Citations

Health related quality of life in prostate carcinoma patients

Efficace

Bottomley

Andel

2003

Cancer

View full text Add to dashboard Cite

Extensive lattice‐Boltzmann simulations were performed to obtain the drag force for random arrays of monodisperse and bidisperse spheres. For the monodisperse systems, 35 different combinations of the Reynolds number Re (up to Re = 1,000) and packing fraction ϕ were studied, whereas for the bidisperse systems we also varied the diameter ratio (from 1:1.5 to 1:4) and composition, which brings the total number of different systems that we considered to 150. For monodisperse systems, the data was found to be markedly different from the Ergun equation and consistent with a correlation, based on similar type of simulations up to Re = 120. For bidisperse systems, it was found that the correction of the monodisperse drag force for bidispersity, which was derived for the limit Re = 0, also applies for higher‐Reynolds numbers. On the basis of the data, a new drag law is suggested for general polydisperse systems, which is on average within 10% of the simulation data for Reynolds numbers up to 1,000, and diameter ratios up to 1:4. © 2007 American Institute of Chemical Engineers AIChE J, 2007.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Hrqol Assessment Methodologymentioning

confidence: 99%

See 1 more Smart Citation

Health related quality of life in prostate carcinoma patients

Efficace

Bottomley

Andel

2003

Cancer

View full text Add to dashboard Cite

show abstract

“…This combines the DPD inhibitor uracil and tegafur, which is converted to 5-FU in the liver, at a 4:1 molecular ratio, and has been used for the treatment of colon, lung, breast, gastric and prostate cancers, among others (48)(49)(50)(51)(52)(53). In patients with untreated advanced prostate cancer, combined therapy with UFT and first-line MAB was reported to be tolerable, and effectively delayed the progression to androgen-independence (54)(55)(56). At the 2010 American Society of Clinical Oncology (ASCO) annual meeting, we reported that combination therapy with uft and second-line MAB was more effective than second-line MAB alone in a study of 53 patients with HRPC (2010 ASCO Annual Meeting abs.…”

Section: Discussionmentioning

confidence: 99%

Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells

Kawabata

Oie²,

Oka³

et al. 2011

Int J Oncol

View full text Add to dashboard Cite

Abstract.We investigated the antitumor effects of combination therapy with anti-androgens and 5-fluorouracil (5-FU), and examined the underlying mechanism of the treatment. Initially, we established the bicalutamide-resistant subline CDX25R from the androgen receptor (AR)-positive human prostate cancer cell line LNCaP through continuous exposure to bicalutamide. CDX25R cells lost the ability to respond to androgens, but still expressed AR. They showed significant resistance to bicalutamide, but had high sensitivity to hydroxyflutamide (OH-flutamide) compared with LNCaP cells. The CDX25R subline was thus considered to be a suitable model for prostate cancer that has developed resistance to first-line hormonal therapy but shows sensitivity to an alternative approach. Combined treatment with 5-FU and OH-flutamide had a synergistic effect on CDX25R cells. OH-flutamide decreased expression of the transcription factor e2f1, and subsequently of thymidylate synthase (TS), in CDX25R cells but not in AR-negative DU145 cells. This suggested that OH-flutamide enhanced the growth-inhibitory activity of 5-FU in CDX25R cells by reducing TS expression through the AR pathway. Combined therapy with 5-FU and OH-flutamide may, therefore, be appropriate for patients with prostate cancer that has acquired resistance to initial hormone therapy including bicalutamide.

show abstract

“…Kuriyama et al [23] reported on the use of daily uracil and tegafur (UFT; in a molar ratio of 4:1) in combination with orchiectomy and DES compared with orchiectomy and DES treatment alone. Progression-free survival improvement on addition of UFT was not quite statistically signifi cant for the whole cohort (51.…”

Section: Preclinical Evaluation Of Taxanes Alone or In Combination Wimentioning

confidence: 99%

Does chemotherapy have a role before hormone-resistant disease develops?

Dean¹,

Higano

2009

Curr Urol Rep

View full text Add to dashboard Cite

Recent studies have demonstrated a survival benefit for chemotherapy in metastatic hormone-resistant prostate cancer. In other malignancies such as breast or colorectal cancer, use of active chemotherapy regimens earlier in the course of the disease has resulted in improvements in disease-free and overall survival. This review discusses the status of chemotherapy in prostate cancer and addresses evidence regarding the use of chemotherapy in hormone-sensitive disease, alone and in combination with androgen deprivation therapy.

show abstract

Prospective and Randomized Comparison of Combined Androgen Blockade Versus Combination with Oral UFT as an Initial Treatment for Prostate Cancer

Abstract: This endocrine chemotherapy was confirmed to be tolerable and significantly effective in the delay of disease progression, which leads to longer survival in patients with prostate cancer.

Cited by 15 publications

References 18 publications

Health related quality of life in prostate carcinoma patients

Health related quality of life in prostate carcinoma patients

Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells

Does chemotherapy have a role before hormone-resistant disease develops?

Contact Info

Product

Resources

About